In 2008, Endo Pharmaceuticals, a U.S. firm, signed a 5-year contracted with Novartis, a Swiss firm, to

Question:

In 2008, Endo Pharmaceuticals, a U.S. firm, signed a 5-year contracted with Novartis, a Swiss firm, to obtain the exclusive U.S. marketing rights for Voltaren Gel, an anti-inflammatory useful in treating osteoarthritis. Search the Internet for information about the contract. Who bore the real exchange risk?